Skip to main content
SpringerLink
Log in

Hematopoietic Stem Cell Donor Selection and Graft-Versus-Host Disease

  • Chapter
  • First Online:
Chimerism

  • 435 Accesses

Abstract

Hematopoietic progenitor cell (HPC; stem cell) transplants represent a key management option for patients with severe disorders, particularly benign or malignant hematological diseases. However, in order to successfully perform a stem cell transplant, it is vital to determine the optimal source of HPCs to serve as a graft, as well as understand the strengths and limitations of these products. Moreover, it is important to understand the potential complications associated with HPC. As such, the aims of this chapter are as follows: (1) to review the types of stem cell sources available for transplant and how they are collected, (2) to discuss HLA and ABO compatibility in the setting of HPC transplant, (3) to understand the potential side effects of stem cell engraftment/transplantation, and (4) to assess possible treatments for side effects that pertain to transfusion medicine and apheresis services.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Wingard JR, Gastineau DA, Leather HL, et al. Hematopoietic progenitor cell transplantation: a clinician’s handbook. 2nd ed. Bethesda: AABB Press; 2016.

    Google Scholar 

  2. Preynat-Seauve O, Krause KH. Stem cell sources for regenerative medicine: the immunological point of view. Semin Immunopathol. 2011;33:519–24.

    Article  PubMed  Google Scholar 

  3. Jaing TH. Umbilical cord blood: a trustworthy source of multipotent stem cells for regenerative medicine. Cell Transplant. 2014;23:493–6.

    Article  PubMed  Google Scholar 

  4. Center for International Blood and Marrow Transplant Research (CIBMTR) homepage. Accessed at: https://www.cibmtr.org/Pages/index.aspx.

  5. Weisdorf DJ. Reduced-intensity versus myeloablative allogeneic transplantation. Hematol Oncol Stem Cell Ther. 2017;10(4):321–6.

    Article  PubMed  Google Scholar 

  6. Tiercy JM. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica. 2016;101:680–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. National Marrow Donor Program (NMDP) homepage. Accessed at: https://bethematch.org/.

  8. Powley L, Brown C, Melis A, Li Y, Parkes G, Navarrete CV. Consideration of noninherited maternal Ags as permissible HLA mismatches in cord blood donor selection. Bone Marrow Transplant. 2016;51:675–9.

    Article  CAS  PubMed  Google Scholar 

  9. Van der Zanden HGM, Van Rood JJ, Oudshoorn M, Bakker JNA, Melis A, Brand A, Scaradavou A, Rubinstein P. Noninherited maternal antigens identify acceptable HLA mismatches: benefit to patients and cost-effectiveness for cord blood bank. Biol Blood Marrow Transplant. 2014;20:1791–5.

    Article  Google Scholar 

  10. Worel N, Kalhs P. AB0-incompatible allogeneic hematopoietic stem cell transplantation. Haematologica. 2008;93:1605–7.

    Article  PubMed  Google Scholar 

  11. Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF, Barrett AJ, Childs RW. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001;98:1687–94.

    Article  CAS  PubMed  Google Scholar 

  12. Dahl D, Hahn A, Koenecke C, Heuft HG, Dammann E, Stadler M, Buchholz S, Krauter J, Eder M, Sykora KW, Klein C, Ganser A, Sauer M. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk. Transfusion. 2010;50:649–55.

    Article  PubMed  Google Scholar 

  13. Zachary AA, Leffell MS. Desensitization for solid organ and hematopoietic stem cell transplantation. Immunol Rev. 2014;258:183–207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bierman PJ, Warkentin P, Hutchins MR, Klassen LW. Pure red cell aplasia following ABO mismatched marrow transplantation for chronic lymphocytic leukemia: response to antithymocyte globulin. Leuk Lymphoma. 1993;9:169–71.

    Article  CAS  PubMed  Google Scholar 

  15. Stussi G, Halter J, Schanz U, Seebach JD. ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation. Transfus Apher Sci. 2006;35:59–69.

    Article  PubMed  Google Scholar 

  16. Sackett K, Cohn CS, Fahey-Ahrndt K, Smith AR, Johnson AD. Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. J Clin Apher. 2018;33(1):108–12.

    Article  PubMed  Google Scholar 

  17. Lasky LC. The role of the laboratory in marrow manipulation. Arch Pathol Lab Med. 1991;115:293–8.

    PubMed  CAS  Google Scholar 

  18. Hows J, Beddow K, Gordon-Smith E, Branch DR, Spruce W, Sniecinski I, Krance RA, Petz LD. Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation. Blood. 1986;67:177–81.

    PubMed  CAS  Google Scholar 

  19. Iwanaga S, Sakaguchi T, Nakanishi K, Furukuwa M, Ishizeki K, Kogawa K, Tsuji A. Passenger lymphocyte syndrome with hemophagocytic syndrome after peripheral blood stem-cell transplantation from an HLA-matched full biological sibling: case report. Transfus Apher Sci. 2012;47:355–8.

    Article  PubMed  Google Scholar 

  20. Cunard R, Marquez II, Ball ED, Nelson CL, Corringham S, Clopton P, Sanchez AP, Lane T, Ward DM. Prophylactic red blood cell exchange for ABO-mismatched hematopoietic progenitor cell transplants. Transfusion. 2014;54:1857–63.

    Article  PubMed  Google Scholar 

  21. Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296–307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010;17:493–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Subramaniam DS, Fowler DH, Pavletic SZ. Chronic graft-versus-host disease in the era of reduced-intensity conditioning. Leukemia. 2007;21:853–9.

    Article  CAS  PubMed  Google Scholar 

  24. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.

    Article  CAS  PubMed  Google Scholar 

  25. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood. 2005;105:4200–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–70.

    Article  CAS  PubMed  Google Scholar 

  28. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945.

    Article  PubMed  Google Scholar 

  29. Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012;158:30.

    Article  CAS  PubMed  Google Scholar 

  30. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100(9):3108–14.

    Article  CAS  PubMed  Google Scholar 

  31. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103(4):1548–56.

    Article  CAS  PubMed  Google Scholar 

  32. Basak GW, de Wreede LC, van Biezen A, Wiktor-Jedrzejczak W, Halaburda K, Schmid C, Schaap N, Dazzi F, von dem Borne PA, Petersen E, Beelen D, Abayomi A, Volin L, Buzyn A, Gurman G, Bunjes D, Guglielmi C, Olavarria E, de Witte T. Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation. Bone Marrow Transplant. 2013;48:837–42.

    Article  CAS  PubMed  Google Scholar 

  33. Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood Rev. 2013;27:55–62.

    Article  CAS  PubMed  Google Scholar 

  34. Dominietto A, Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Berisso G, Bregante S, Frassoni F, Casarino L, Verdiani S, Bacigalupo A. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 2001;112:219–27.

    Article  CAS  PubMed  Google Scholar 

  35. Fung W, Eder AF, Spitalnik SL, Westhoff CM, editors. Technical manual. 19th ed. Bethesda: AABB Press; 2017.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Yale University School of Medicine, New Haven, CT, USA

    Alexa J. Siddon MD

  2. Pathology and Laboratory Medicine Service, VA Connecticut HealthCare System, West Haven, CT, USA

    Alexa J. Siddon MD & Christopher A. Tormey MD

  3. Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA

    Alexa J. Siddon MD & Christopher A. Tormey MD

Authors
  1. Alexa J. Siddon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher A. Tormey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher A. Tormey MD .

Editor information

Editors and Affiliations

  1. Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado, USA

    Nicole L. Draper

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Siddon, A.J., Tormey, C.A. (2018). Hematopoietic Stem Cell Donor Selection and Graft-Versus-Host Disease. In: Draper, N. (eds) Chimerism. Springer, Cham. https://doi.org/10.1007/978-3-319-89866-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-89866-7_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-89865-0

  • Online ISBN: 978-3-319-89866-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation